Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.51 |
| ▸ | PANK3 | Q9H999 | 7/20 | 0.49 |
| ▸ | PARP1 | P09874 | 4/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | SMO | Q99835 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28982891 | 0.85 | PARP1 (0.58) | CHRM4PANK3PARP1PARP2CHRM1 | |
| SCHEMBL26125148 | 0.85 | PARP1 (0.58) | CHRM4PANK3PARP1PARP2CHRM1 | |
| SCHEMBL25264632 | 0.85 | CHRM4 (0.48) | CHRM4PARP1CHRM1CHRM2CHRM5 | |
| SCHEMBL22638185 | 0.83 | ME2 (0.51) | — | |
| SCHEMBL3787774 | 0.83 | CHRM4 (0.49) | CHRM4PANK3PARP1PARP2 | |
| SCHEMBL25273965 | 0.82 | GRM1 (0.43) | CHRM4 | |
| SCHEMBL21854001 | 0.81 | PARP1 (0.61) | CHRM4PANK3PARP1PARP2DPP4 | |
| SCHEMBL25207018 | 0.81 | PANK3 (0.51) | CHRM4PANK3 | |
| SCHEMBL4508825 | 0.79 | GRM4 (0.42) | CHRM4 | |
| SCHEMBL26620008 | 0.79 | MEN1 (0.55) | PANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | CHRM4 1039/4885PANK3 776/4885PARP1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.